Letrozole

Form: Tablets

Strength: 2.5 mg

Reference Brands: Femara® (US & EU)

Category: Oncology Cancer Care

Letrozole, sold under the brand name Femara®, is a highly effective aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Approved in both the US and EU, Letrozole is available in 2.5 mg oral tablets and is widely prescribed for early and advanced-stage breast cancer. As a key hormonal therapy, Letrozole is sourced globally by B2B pharmaceutical wholesalers, hospitals, and oncology clinics. With GMP-compliant manufacturing and reliable supply chains, Letrozole offers consistent quality and competitive pricing in the European and American markets, supporting cancer care with trusted pharmaceutical standards.